TORONTO, ON / ACCESSWIRE / October 12, 2021 / Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) ("Predictmedix" or the "Company"), an emerging provider of rapid health screening solutions powered by a proprietary artificial intelligence (AI), today announced the official launch of its next-generation, revamped corporate website www.predictmedix.com, reflecting ongoing efforts to provide up-to-date information for both prospective customers and investors.

The new website has been designed to be more dynamic, user friendly and content rich - best showcasing the Company's AI technologies for health and safety in workplaces and healthcare. It offers a clean, modern design integrated with helpful information and custom landing pages for marketing to customers considering the Company's proprietary Safe Entry Station rapid screening solution. The website also features an updated investor relations section including press releases, the current share price, regulatory filings and more.

"Our new website will give Predictmedix an enhanced online marketing presence that highlights our AI-powered products for corporate customers and investors," said Dr. Rahul Kushwah, Chief Operating Officer of Predictmedix. "With a focus on automated rapid screening for COVID-19 in offices, manufacturing, warehouses, seniors' facilities and at large events, the website better demonstrates our wide array of solutions to generate new sales leads.

"The investor relations pages provide our shareholders and prospective investors with current, easily accessible information about our operations, business strategy, stock profile and more, reflecting our ongoing commitment to enhance transparency and shareholder communications. The Company has made substantial operational achievements in recent months, including significant progress in securing tier-1 deployments of our Safe Entry Stations with clients around the world, and a refreshed website will help us to continue to elevate our profile."

About Predictmedix Inc.

Predictmedix (CSE:PMED) (OTCQB: PMEDF) is a leading provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including infectious diseases such as COVID-19, impairment by drugs or alcohol, or various mental illnesses. Predictmedix's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.

Investor Relations Contact
Lucas A. Zimmerman
MZ Group - MZ North America
949-259-4987
PMEDF@mzgroup.us
www.mzgroup.us

Caution Regarding Forward-Looking Information:

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time."

SOURCE: Predictmedix